BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1110 related articles for article (PubMed ID: 30536183)

  • 1. Contribution of the OC Sensor
    Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
    Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan.
    Ou CH; Kuo FC; Hsu WH; Lu CY; Yu FJ; Kuo CH; Wang JY; Wu MT; Shiea J; Wu DC; Hu HM
    J Dig Dis; 2013 Sep; 14(9):474-83. PubMed ID: 23701988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of two colorectal cancer screening campaigns using different faecal occult blood tests in a French area.
    Cariou M; El Fettouhi A; Kermarrec T; Bommelaere F; Foll Y; Nousbaum JB; Robaszkiewicz M; Quénéhervé L
    Cancer Epidemiol; 2020 Dec; 69():101839. PubMed ID: 33096500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer.
    Faivre J; Dancourt V; Denis B; Dorval E; Piette C; Perrin P; Bidan JM; Jard C; Jung S; Levillain R; Viguier J; Bretagne JF
    Eur J Cancer; 2012 Nov; 48(16):2969-76. PubMed ID: 22572481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
    Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
    Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
    Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition to quantitative faecal immunochemical testing from guaiac faecal occult blood testing in a fully rolled-out population-based national bowel screening programme.
    Clark G; Strachan JA; Carey FA; Godfrey T; Irvine A; McPherson A; Brand J; Anderson AS; Fraser CG; Steele RJ
    Gut; 2021 Jan; 70(1):106-113. PubMed ID: 32234803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
    Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
    Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
    Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L
    Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening.
    Shapiro JA; Bobo JK; Church TR; Rex DK; Chovnick G; Thompson TD; Zauber AG; Lieberman D; Levin TR; Joseph DA; Nadel MR
    Am J Gastroenterol; 2017 Nov; 112(11):1728-1735. PubMed ID: 29016558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.
    Guittet L; Bouvier V; Mariotte N; Vallee JP; Arsène D; Boutreux S; Tichet J; Launoy G
    Gut; 2007 Feb; 56(2):210-4. PubMed ID: 16891354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
    Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme.
    Faivre J; Dancourt V; Manfredi S; Denis B; Durand G; Gendre I; Bidan JM; Jard C; Levillain R; Jung S; Viguier J; Dorval E
    Dig Liver Dis; 2012 Aug; 44(8):700-4. PubMed ID: 22542582
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 56.